The pathogenic events leading to FSHD have recently started coming into focus. Several studies now support that FSHD is ultimately caused by de-repression of the DUX4 gene, which encodes a pro-apoptotic transcription factor. The emergence of DUX4 as a pathogenic insult in FSHD now makes it possible to begin developing targeted therapies for this currently untreatable disorder. The long-term goal of this proposal is to develop a therapeutic approach for FSHD through DUX4 inhibition. The objective here is to reduce DUX4 expression and activity using RNAi and novel protein therapies.
The specific aims of this proposal are expected to demonstrate pre-clinical, in vivo proof-of-principle data on the efficacy of two therapeutic approaches. As such, the specific aims of this proposal are: (1) To develop a DUX4-targeted RNAi-based gene therapy for FSHD, and (2) To develop a dominant negative DUX4 therapy for FSHD. This proposal is significant and innovative because it represents the first steps toward a translational strategy for a targeted FSHD therapy.

Public Health Relevance

Elevated levels of the DUX4 gene have been recently linked to development of Facioscapulohumeral Muscular Dystrophy (FSHD), one of the most common diseases of muscle. We propose that inhibiting DUX4 expression and activity in muscles will improve muscular dystrophy in FSHD patients. In this proposal, we will test two DUX4 inhibition strategies using gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS078327-02
Application #
8442833
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Porter, John D
Project Start
2012-04-01
Project End
2014-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
2
Fiscal Year
2013
Total Cost
$174,665
Indirect Cost
$54,040
Name
Nationwide Children's Hospital
Department
Type
DUNS #
147212963
City
Columbus
State
OH
Country
United States
Zip Code
43205
Wallace, Lindsay M; Saad, Nizar Y; Pyne, Nettie K et al. (2018) Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev 8:121-130
Wallace, Lindsay M; Moreo, Andrew; Clark, K Reed et al. (2013) Dose-dependent Toxicity of Humanized Renilla reniformis GFP (hrGFP) Limits Its Utility as a Reporter Gene in Mouse Muscle. Mol Ther Nucleic Acids 2:e86
Wallace, Lindsay M; Liu, Jian; Domire, Jacqueline S et al. (2012) RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther 20:1417-23
Wallace, Lindsay M; Garwick, Sara E; Mei, Wenyan et al. (2011) DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol 69:540-52